Toubro Søren, Astrup Arne V
Københavns Universitet, Det Biomedicinske Fakultet, Institut for Human Ernaering, og Reduce - en forskningsklinik, og Gentofte Hospital, Klinisk Ernaeringsenhed, Denmark.
Ugeskr Laeger. 2010 Feb 15;172(7):534-6.
The prevalence of overweight and obesity exceed 50% in many European countries. Obesity is responsible for 2-8% of all health costs and 10-13% of all deaths in Europe. Only a fraction of patients obtain a medically relevant weight loss of 5-10% through lifestyle intervention. Surgery is limited to severe obesity and is very costly; therefore pharmaceuticals are a relevant alternative. Such treatment is hampered by the lack of official guidelines and a relatively limited effect compared to the expectations of patients as well as medical staff. Guidelines and official subsidies are debated.
在许多欧洲国家，超重和肥胖的患病率超过了50%。在欧洲，肥胖导致的医疗费用占总医疗费用的2%至8%，死亡人数占总死亡人数的10%至13%。只有一小部分患者通过生活方式干预实现了具有医学意义的5%至10%的体重减轻。手术仅限于重度肥胖患者，且费用高昂；因此，药物治疗是一种可行的替代方案。由于缺乏官方指南，且与患者及医护人员的期望相比效果相对有限，这种治疗受到了阻碍。关于指南和官方补贴的讨论正在进行。
